Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models
详细信息 查看全文
- 作者：Thomas Kramer ; Fabio Lo Monte ; Stefan G枚ring ; Ghislaine Marlyse Okala Amombo ; Boris Schmidt
- 刊名：ACS Chemical Neuroscience
- 出版年：2012
- 出版时间：March 21, 2012
- 年：2012
- 卷：3
- 期：3
- 页码：151-160
- 全文大小：368K
- 年卷期：v.3,no.3(March 21, 2012)
- ISSN：1948-7193
文摘
Parkinson's disease (PD) is the second most common neurodegenerative disorder. Several single gene mutations have been linked to this disease. Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) indicate LRRK2 as promising therapeutic target for the treatment of PD. LRRK2 mutations were observed in sporadic as well as familial PD patients and have been investigated intensively. LRRK2 is a large and complex protein, with multiple enzymatic and protein-interaction domains, each of which is effected by mutations. The most common mutation in PD patients is G2019S. Several LRRK2 inhibitors have been reported already, although the crystal structure of LRRK2 has not yet been determined. This review provides a summary of known LRRK2 inhibitors and will discuss recent in vitro and in vivo results of these inhibitors.